Morale in MSBU at all time low

So true! Any yet he and his boys are always safe. And now his boy Richard R is leading primary care. Geez.

 

"Take a look at Novartis' ($NVS) second-quarter results for reasons why it engineered that big asset swap-and-sale with GlaxoSmithKline ($GSK) and Eli Lilly ($LLY). The two units Novartis is unloading, vaccines and animal health, delivered weak sales for the quarter, dragging the company's top line below expectations.

The Swiss drugmaker's pharma group didn't exactly shine either, though. Branded drug sales barely ticked upward, . . . . "

"It was Sandoz, the generics division, that delivered the biggest boost, growth-wise, with a 5% year-over-year increase. Overall, Q2 revenue grew by 2% to $14.64 billion, a tad lower than the average analyst forecast, the Financial Times notes."

"Don't expect much better for the rest of the year, either; the company confirmed its forecast of low- to mid-single digit sales growth, . .. That's because Novartis is finally facing full-on generic competition . . . "

"Those savings won't come overnight, though, Jimenez warns." . . . . "This is going to be a process over time that allows us to continually lower our costs and continually drive margin growth."

http://www.fiercepharma.com/story/no...fit/2014-07-17

 

Biogen spanking that Gilenya azz all day everyday.

 

No surprise there. The only competitor Biogen could never spank was Copaxone. Novartis in MS was a joke from the start. Lower share than Rebif. Haha